The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis.
Overstreet AM, LaTorre DL, Abernathy-Close L, Murphy SF, Rhee L, Boger AM, Adlaka KR, Iverson AM, Bakke DS, Weber CR, Boone DL.
Overstreet AM, et al. Among authors: iverson am.
Mucosal Immunol. 2018 Sep;11(5):1454-1465. doi: 10.1038/s41385-018-0051-2. Epub 2018 Jul 9.
Mucosal Immunol. 2018.
PMID: 29988117
Free PMC article.